Re: Update to Communicable Disease Control Manual, Chapter 1: *Haemophilus influenzae* type b and Chapter 2: Immunization, Part 4 – Biological Products

**Chapter 1: Communicable Disease Control**

*Haemophilus influenzae* type b

The following are the key revisions and updates:

- 5.0 Reporting has been revised to include a link to the “Invasive *Haemophilus influenzae* type b” surveillance form. The new case report form facilitates enhanced surveillance for invasive Hib disease, which was approved by the Communicable Disease Policy Advisory Committee on January 17, 2023.
- 6.1.1 The section title has been updated to ‘Immunoprophylaxis of Adults in Delineated Communities Following Occurrence of a Cluster or Case’
  - Content under this section has been added to allow for Hib vaccine to be offered to close ‘household-type’ contacts following the occurrence of an invasive case in an adult associated with the homeless/ under-housed population at the discretion of the regional MHO. This approach was approved by CD MHOs and health authority leads in December 2022.

**Please remove entire section:** dated December 2022

**Please add new section:** dated January 2023
Chapter 2: Immunization

Part 4 – Biological Products

COVID-19 Vaccines

The BOOSTER DOSES content for the following COVID-19 mRNA vaccine product pages has been revised to allow for individuals 12 years of age and older who received a monovalent COVID-19 mRNA vaccine booster dose during the Fall 2022 Booster Dose Program to be offered a bivalent COVID-19 mRNA vaccine at the recommended interval of at least 6 months.

**COVID-19 mRNA Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) Adult/Adolescent**

Please remove page numbers: 1-4 dated January 2023
Please add new page numbers: 1-4 dated January 27, 2023

**COVID-19 mRNA Vaccine SPIKEVAX™ Bivalent (Moderna) Original/Omicron**

Please remove page numbers: 1-4 dated January 2023
Please add new page numbers: 1-4 dated January 27, 2023

**COVID-19 mRNA Vaccine SPIKEVAX™ Bivalent (Moderna) Original/Omicron BA.4/5**

Please add new page numbers: 1-4 dated January 2023
Please add new page numbers: 1-4 dated January 27, 2023

Pneumococcal Vaccines

**Pneumococcal Conjugate Vaccine: PREVNAR® 13**

SPECIAL CONSIDERATIONS: Content has been added for PCV15 and PCV20. While these products are approved for use by Health Canada, they are not currently publicly funded in BC, nor has NACI made a recommendation on their use in Canada. Per ACIP recommendation, PCV13 and PCV15 can be used interchangeably within a series. If PPV23 is indicated, when PCV15 is provided first, there should be a minimum interval of 8 weeks between doses. If PPV23 has already been administered, a PCV should be administered at least one year later. If PCV20 has been provided, PPV23 is not required.

Please add new page numbers: 1-3 dated June 2022
Please add new page numbers: 1-3 dated January 2023
Pneumococcal Polysaccharide Vaccine: PNEUMOVAX® 23

- **INDICATIONS:** Language for some indications has been revised for clarity and inclusivity.
- **SPECIAL CONSIDERATIONS:** Content has been added for PCV15 and PCV20. While these products are approved for use by Health Canada, they are not currently publicly funded in BC, nor has NACI made a recommendation on their use in Canada. If PPV23 is indicated, when PCV15 is provided first, there should be a minimum interval of 8 weeks between doses. If PPV23 has already been administered, a PCV should be administered at least one year later. If PCV20 has been provided, PPV23 is not required.

*Please add new page numbers: 1-2 dated October 2018*
*Please add new page numbers: 1-3 dated January 2023*

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

**pc:**
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention, Population and Public Health Division